Haemonetics Co. (NYSE:HAE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Haemonetics Co. (NYSE:HAE) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $106.14.

A number of research firms have recently weighed in on HAE. Barrington Research reaffirmed an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a research report on Monday, September 23rd. Citigroup cut their price objective on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Bank of America began coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective on the stock. BTIG Research began coverage on Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price objective on the stock. Finally, CL King began coverage on Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 price objective on the stock.

Hedge Funds Weigh In On Haemonetics

Several large investors have recently bought and sold shares of HAE. Quarry LP acquired a new position in Haemonetics in the second quarter valued at $39,000. Covestor Ltd boosted its stake in Haemonetics by 184.8% in the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after acquiring an additional 438 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in Haemonetics in the second quarter valued at $82,000. Canada Pension Plan Investment Board acquired a new position in Haemonetics in the second quarter valued at $83,000. Finally, EntryPoint Capital LLC acquired a new position in Haemonetics in the first quarter valued at $86,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 1.2 %

NYSE:HAE opened at $71.15 on Friday. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35. The stock’s fifty day moving average is $75.55 and its two-hundred day moving average is $82.86. Haemonetics has a 52 week low of $70.25 and a 52 week high of $97.97. The stock has a market capitalization of $3.64 billion, a price-to-earnings ratio of 31.91, a price-to-earnings-growth ratio of 1.16 and a beta of 0.30.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. During the same quarter last year, the company earned $1.05 earnings per share. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. Research analysts anticipate that Haemonetics will post 4.57 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.